FDA approves BridgeBio’s Attruby for ATTR-CM treatment
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
Emcure has launched an awareness campaign to help spread the word about male anemia
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Revenue from Operations during Q2 FY25 was Rs. 3,077 crore as compared to Rs. 2,708 crore in Q2 FY24.
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Subscribe To Our Newsletter & Stay Updated